<DOC>
	<DOCNO>NCT00777998</DOCNO>
	<brief_summary>The present study multicenter , prospective phase II-study investigating safety efficacy combination auto-allo tandem stem cell transplantation patient multiple myeloma age &gt; _60 year , follow maintenance therapy low-dose Thalidomide Donor Lymphocyte Infusions .</brief_summary>
	<brief_title>Auto-Allo Tandem Stem Cell Transplantation Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Ferrous fumarate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Multiple Myeloma Stage II III acc . Salmon Durie Patient 's age 1860 year Patient 's write informed consent Women men capable reproduction must agree use adequate contraceptive measure ( condom , IUD , oral contraceptive ) three month termination treatment maximum eight chemotherapy cycle prior registration ( CR/ PR/ MR/ PD ) More eight chemotherapy cycle prior registration severe irreversible renal , hepatic , pulmonary cardiac disease , total bilirubin , SGPT SGOT &gt; 3 time upper normal level Left ventricular ejection fraction &lt; 30 % Creatinine Clearance &lt; 30 ml/min DLCO &lt; 35 % and/or receive supplementary continuous oxygen Positive serology HIV Pregnant lactate woman Participation another trial time registration Preceding autologous stem cell transplantation age &gt; 61 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>DLI</keyword>
</DOC>